Dr. Reddy's Laboratories Ltd.’s Announces the Launch of Rivastigmine Tartrate Capsules

Published: Sep 22, 2011

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Rivastigmine Tartrate Capsules (1.5 mg, 3 mg, 4.5 mg and 6 mg), a bioequivalent generic version of EXELON®* Capsules in the US market on September 15, 2011 following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy’s ANDA for Rivastigmine tartrate capsules.

Back to news